PitchBook has published its 2021 U.S. Venture Capital Outlook report. The report predicts venture capital (VC) activity and performance for next year.

One of the key projections is that for the second consecutive year, biotech and pharma VC deal activity will probably exceed $20 billion. They think this is being fueled by growing capital commitments from VC investors hoping to enter the biopharma space, as well as recycling of profits and liquidity from this year’s initial public offering (IPO) market. READ MORE